- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Short bowel syndrome (SBS)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1032KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 76KB)
Teduglutide – March 2021
Teduglutide: Powder for injection 5 mg with diluent; Revestive®
Last updated
2 July 2021